00013 HUTCHMED
- 30.250
- -0.750-2.42%
HUTCHMED News
Does HUTCHMED (HCM) Have the Potential to Rally 38.13% as Wall Street Analysts Expect?
Hong Kong Stock Concept Tracking | ASCO Research Title Publishers Focus on Opportunities in the Domestic Innovative Drug Industry (with concept stocks)
After years of cultivation, domestically produced innovative drugs have reached the initial stage of producing results, and ASCO's participation has further increased in '24
HUTCHMED Shares Are Trading Higher. The Company on Friday Announced a Positive CHMP Opinion for Fruquintinib.
HUTCHMED Shares Are Trading Higher. The Company on Friday Announced a Positive CHMP Opinion for Fruquintinib.
HUTCHMED Nears EU Approval for Cancer Drug
Hehuang Pharmaceutical (0013.HK): Fruquintiniol will be approved soon and can be expected to be released overseas
Guide to this report: The sales trend of fruquintinib in the US is improving. Europe and Japan are expected to be approved within this year, and they are optimistic about the overseas release of fruquintinib. Sevotinib is expected to be submitted to the US NDA by the end of the year, and the innovation pipeline will enter the harvest period one after another, maintaining the “gain” rating. summary
HUTCHMED's Fruquintinib Close to EU Approval
Chu Wong Pharmaceutical (00013.HK): Takeda receives positive feedback from the European Medicines Agency's Human Medicines Committee (CHMP) to support fruquintinib (fruquintinib) for the treatment of metastatic colorectal cancer
On April 26, Gelonghui Pharmaceutical (00013.HK) announced that its partner Takeda (TSE: 4502/ NYSE: TAK) has obtained the recommendation of the European Medicines Agency (EMA) Commission for Human Medicines (CHMP) to approve fruquintinib for the treatment of treated adult patients with metastatic colorectal cancer. The European Commission (EC) will take the positive comments of CHMP into account when deciding on marketing licensing fruquintinib for the treatment of metastatic colorectal cancer throughout the European Union, Norway, Liechtenstein, and Iceland. If approved, furoquine
HUTCHMED (China) (LON:HCM) Shareholders Are up 8.2% This Past Week, but Still in the Red Over the Last Five Years
Changes in Hong Kong stocks | Hutchison Pharmaceutical (00013) rose nearly 7% in the afternoon, and the volume of furoquintinib was rapidly released after launch, and many major products are expected to be approved for major indications
Hewang Pharmaceutical (00013) rose nearly 7% in the afternoon. As of press release, it had risen 6.13% to HK$28.55, with a turnover of HK$94.6406 million.
HUTCHMED Announces Key Managerial LTIP Vesting
HUTCHMED Executives' Incentive Plan Vested
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Ping An Securities: Maintaining the “Recommended” Rating of Hewang Pharmaceutical (00013.HK), 2023 results are in line with expectations
Ping An Securities released a research report stating that considering that the indications for the company's listed products are still expanding, and the pipeline valuation is expected to further improve, maintaining the “recommended” rating of Hehuang Pharmaceutical (00013.HK), the main business revenue for 2024-2026 is estimated to be US$6.71, 8.61, and 1,027 million US dollars, respectively, and net profit of -1.07, 0.2, and 95 million US dollars, respectively, in line with the previous one. The company's total revenue in 2023 was US$838 million (yoy+97%), of which the comprehensive revenue from the oncology/immunology business was US$529 million (yoy+223)
Hutchison Pharmaceutical (0013.HK): 23-year performance is in line with expectations, intensive catalysis in the global innovation pipeline
Matters: On April 8, 2024, Hutchison Pharmaceutical announced its 2023 annual report. The company's total revenue was US$838 million (yoy +97%), of which the comprehensive revenue from the oncology/immunology business was US$529 million (yoy+
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Changes in Hong Kong stocks | Hutchison Pharmaceutical (00013.HK) is now up nearly 6%. The company announced data at the AACR annual meeting that furoquintinib was released rapidly after listing in the US
Hewang Pharmaceutical (00013.HK) is now up nearly 6%. As of press release, it is up 5.21% to HK$28.25, with a turnover of HK$586.912 million.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
HUTCHMED: 2023 Annual Report
Analysis
Price Target
No Data
